Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 20 ug subcutaneous once daily
LIXI_SC_20UG_QD
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.29 (-0.55 to -0.03) | 0.08 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.42 (-0.75 to -0.07) | 0.15 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin glargine | MD 0.50 (-0.47 to 1.58) | 0.07 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.88 (-1.51 to -0.23) | 0.54 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.55 (-1.04 to -0.09) | 0.98 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.58 (-0.96 to -0.14) | 0.61 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.30 (-1.32 to 0.74) | 0.34 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.13 (-1.98 to -0.29) | 0.40 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.14 (-2.45 to 0.14) | 0.62 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin glargine | MD -2.79 (-7.65 to 1.95) | 0.82 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.97 (-2.21 to 0.34) | 0.96 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.53 (-1.70 to 0.79) | 0.48 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.87 (-5.61 to 4.29) | 0.45 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 1.61 (0.59 to 3.45) | 0.13 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 1.91 (0.95 to 3.14) | 0.17 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Insulin glargine | OR 0.28 (0.10 to 0.96) | 0.02 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.70 (1.42 to 4.92) | 0.99 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 1.99 (0.50 to 6.47) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.47 (0.11 to 1.60) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.59 (0.26 to 1.33) | 0.81 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.50 (1.09 to 2.10) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.56 (0.14 to 2.11) | 0.64 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 3.17 (-3.09 to 9.47) | 0.11 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.61 (0.65 to 4.08) | 0.27 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.61 (0.55 to 4.57) | 0.22 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.79 (1.10 to 3.00) | 0.99 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.57 (0.40 to 6.29) | 0.49 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.06 (0.87 to 1.28) | 0.44 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.28 (1.50 to 3.49) | 0.37 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.97 (3.34 to 4.79) | 0.32 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.98 (3.07 to 5.26) | 0.36 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.15 (0.95 to 1.40) | 0.66 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.50 (0.98 to 2.34) | 0.54 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 6.61 (1.62 to 39.34) | 0.19 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.32 (0.03 to 3.28) | 0.68 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 2.06 (0.07 to 92.68) | 0.32 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 0.68 (0.07 to 10.72) | 0.73 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 3.27 (0.16 to 128) | 0.45 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.59 (0.30 to 9.25) | 0.40 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.39 (0.22 to 9.73) | 0.62 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 1.17 (0.27 to 5.59) | 0.75 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 1.40 (0.19 to 11.47) | 0.75 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 1.25 (0.22 to 7.76) | 0.73 |
| Chronic kidney disease with diabetes | Constipation | longest follow-up | Placebo | HR 1.67 (0.15 to 21.23) | 0.57 |
Trials
- S002858101 randomized · 24 weeks
- S00305848 randomized · 12 weeks
- Lixilan-O-APA Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)2019 · 878 randomized · 24 weeks
- NCT02803918Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin2017 · 23 randomized · 6 weeks
- LIXILAN JP-O1A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period2016 · 321 randomized · 52 weeks
- NCT02200991A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus2014 · 136 randomized · 4 weeks
- LixiLan-OA Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)2014 · 1,170 randomized · 30 weeks
- GetGoal-OA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen2013 · 350 randomized · 24 weeks
- NCT01632163A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin2012 · 448 randomized · 24 weeks
- GetGoal-M-AsiaEfficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period2010 · 391 randomized · 24 weeks
- NCT01175473An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2010 · 148 randomized · 4 weeks
- GETGOAL-L-ASIAA Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea2009 · 311 randomized · 24 weeks
- GetGoal-Duo1A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin2009 · 446 randomized · 24 weeks
- NCT00976937A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin2009 · 319 randomized · 24 weeks
- GETGOAL-PA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone2008 · 484 randomized · 24 weeks
- GETGOAL-SA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea2008 · 859 randomized · 24 weeks
- GETGOAL-XA Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2008 · 639 randomized · 24 weeks
- GETGOAL-LA Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin2008 · 496 randomized · 24 weeks
- NCT00299871A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus2006 · 542 randomized · 13 weeks